Lakefront Biotherapeutics (LKFT) Cost of Revenue (2021 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cost of Revenue for 6 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• Quarterly Cost of Revenue fell 65.04% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.7 million (down 34.99% YoY) and the FY2025 annual result came in at $33.8 million, down 14.71% from the prior year.
• Cost of Revenue rose to $5.5 million in Q1 2026 per LKFT's latest filing, from $517769.2 in the prior quarter.
• Over the last five years, Cost of Revenue for LKFT reached as high as $20.5 million in Q4 2023 and fell as low as -$609943.5 in Q2 2024.
• A 5-year average of $6.6 million and a median of $4.7 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 7563.16% — and 2024, when it plunged 112.68%.
• Year by year, Cost of Revenue stood at $4.7 million in 2022, then soared by 334.68% to $20.5 million in 2023, then plunged by 90.56% to $1.9 million in 2024, then plunged by 73.24% to $517769.2 in 2025, then soared by 954.73% to $5.5 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $5.5 million, $517769.2, and $12.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.